MG
Meditor Group Portfolio holdings
AUM
$48.1M
This Quarter Return
+10.39%
1 Year Return
+38.67%
3 Year Return
+41.15%
5 Year Return
+72.2%
10 Year Return
+1,065.64%
AUM
$665M
AUM Growth
+$665M
(+19%)
Cap. Flow
+$56M
Cap. Flow
% of AUM
8.43%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
2
Reduced
–
Closed
–
Top Buys
| 1 |
Esperion Therapeutics
ESPR
|
$26.2M |
| 2 |
Exelixis
EXEL
|
$25.8M |
| 3 |
Celldex Therapeutics
CLDX
|
$4.09M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 90.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Exelixis
EXEL
$10.1B
| $498M | 74.97% | 20,229,713 +1,046,000 | +5% | +$25.8M |
|
2
Alkermes
ALKS
$4.78B
| $59.7M | 8.99% | 1,030,639 | – | – |
|
|
3
Esperion Therapeutics
ESPR
$448M
| $26.2M | 3.94% | +566,000 | New | +$26.2M |
|
4
ProShares UltraPro Short S&P 500
SPXU
$527M
| $19.2M | 2.9% | 1,230,000 | – | – |
|
5
ProShares UltraShort S&P500
SDS
$445M
| $16M | 2.4% | 1,260,000 | – | – |
|
6
WisdomTree India Earnings Fund ETF
EPI
$2.86B
| $15.4M | 2.32% | 630,000 | – | – |
|
7
iShares MSCI India ETF
INDA
$9.17B
| $15.4M | 2.32% | 480,000 | – | – |
|
|
8
Celldex Therapeutics
CLDX
$1.47B
| $14.3M | 2.16% | 5,800,000 +1,654,100 | +40% | +$4.09M |
|